Clinical Trials
Phase 1 Pivotal Study in Korea for HLB3-002 Plans to apply for marketing approval with the MFDS by the 2H 2025 -Huonslab Co., Ltd. (&ldq...
May 27, 2025 | News
YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] Cellt...
May 26, 2025 | News
Duality Biotherapeutics partner Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced c...
May 23, 2025 | News
Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, announced that ...
May 21, 2025 | News
AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone Full results published in th...
May 20, 2025 | News
National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade...
May 19, 2025 | News
Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrop...
May 19, 2025 | News
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has...
May 19, 2025 | News
Shanghai Ark Biopharmaceutical Co., Ltd. announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of id...
May 16, 2025 | News
-InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced&nbs...
May 13, 2025 | News
First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North Sydney Recruitment to open this month at Frankston Hospital, ...
May 13, 2025 | News
Minghui Pharmaceutical , a late-stage clinical biopharmaceutical company, announced an exclusive licensing and collaboration agreement with Qilu Phar...
May 12, 2025 | News
CARsgen Therapeutics Holdings Limited a company focused on developing innovative CAR T-cell therapies, announces preliminary clinical data for CT0596...
May 12, 2025 | News
Conducted under U.S. FDA-cleared IND– Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease Connext, a clinical s...
May 09, 2025 | News
Most Read
Bio Jobs
News